The contract economics problem
A small molecule pharma company is built on contracts. License agreements with research partners. Royalty obligations to early-stage discovery sources. Milestone payments tied to clinical, regulatory, and commercial events. Collaboration agreements that split development costs and commercial profits across multiple parties. ASC 606 applies to revenue. ASC 808 applies to collaboration arrangements. Both apply concurrently in most pharma operating models.
ERP systems that track inventory and book invoices do not track obligations, milestones, and contractual triggers as first-class objects. NetSuite, configured for pharma, treats the contract structure as the foundation and lets revenue, expense, and balance sheet entries flow from contract terms. Per Oracle NetSuite's Life Sciences ERP documentation, the platform supports milestone-based revenue recognition and project accounting natively. Archer's work configures these standard features for the contract complexity small molecule pharma actually carries.
The contract is the operating model in small molecule pharma. ERP that treats contracts as reference data, not as the foundation, leaves finance running the company on spreadsheets.
Why generic ERP fails small molecule pharma
Royalty tracking
Royalty obligations vary by jurisdiction, by product, by tier, by step-down clause, by minimum payment guarantee. Generic ERP configurations cannot accommodate this complexity without spreadsheet support. Finance ends up running the books on spreadsheets and using NetSuite as a journal entry destination.
Milestone accounting
Development, regulatory, and commercial milestones trigger revenue, expense, or both. ASC 606 requires variable consideration treatment until the milestone is probable. ASC 808 collaboration accounting has its own treatment. ERP without a milestone object as a first-class entity cannot support either standard cleanly.
R and D capitalization
The shift from expense to capitalization at regulatory approval has to be supported at the item and project level. Generic configurations miss the trigger.
NDA-stage cost tracking
Late-stage development costs are scrutinized by management, board, and investors. Visibility at the cost-per-program level has to come from the ERP, not from a separate FP and A model.
How Archer configures NetSuite for small molecule pharma
Contract structure is built as a parent record with milestone, royalty, and obligation objects underneath. Archer's Contract Lifecycle Management module treats each obligation as a first-class entity. Each milestone carries its own probability assessment, trigger conditions, and revenue or expense treatment. Royalty obligations are calculated automatically against sales activity, with tiered rates, step-downs, and minimums applied in the calculation.
ASC 606 application uses the contract structure to drive performance obligation identification, transaction price allocation, and timing of recognition. Variable consideration is constrained per the standard, with documented methodology.
ASC 808 collaboration accounting runs in parallel where applicable. Cost sharing, profit splits, and reimbursement obligations all flow against the collaboration record.
NDA-stage program cost tracking surfaces in CFO-ready dashboards. Cost-per-program, cost-per-phase, and cost-per-milestone are queryable without spreadsheet support. Sunshine Act Reporting captures HCP transfers of value, which is increasingly important for commercial-stage pharma compliance.
Related on archerinsights.com
- Biotech and pharmaceuticals industry page. Archer's full configuration approach for clinical and commercial pharma.
- Contract Lifecycle Management module. Milestone, royalty, and obligation tracking inside NetSuite.
- Sunshine Act Reporting module. HCP transfer-of-value tracking and CMS Open Payments reporting.
- Specialty pharma industry page. Commercial gross-to-net configuration for launched products.
- CRO industry page. Clinical-stage cost accumulation against CRO services.
- White papers and resources. Healthcare CFO whitepaper series.
External references
- NetSuite Life Sciences ERP
- ASC 606 Revenue Recognition Standard
- FDA 21 CFR Part 11
- Choosing the Right ERP for Life Sciences
Make the contract the foundation of your finance system
A discovery call covers your contract structure, your milestone tracking approach, and the configuration that supports clean ASC 606 and ASC 808 application.